Prostate Cancer - Results from #2060

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. October 5, 2023

Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using Mendelian randomization and tumor spatial transcriptomics. October 5, 2023

Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial. October 5, 2023

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures. October 5, 2023

Age 70 +/- 5 Years and Cancer Specific Outcomes after Treatment of Localized Prostate Cancer: A Systematic Review. October 5, 2023

Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer. October 4, 2023

A Systematic Review and Network Meta-Analysis Assessing the Impact of Adding First Generation Non-Steroidal Anti-Androgens (NSAA) to LHRH Agonists (LHRHa) in Men Receiving Radiotherapy for Localized Prostate Cancer. October 4, 2023

Treatment Delivery Gating of MRI-Guided Stereotactic Radiotherapy for Prostate Cancer: An Exploratory Analysis of a Phase III Randomized Trial of CT-Vs. MR-Guided Radiotherapy (MIRAGE). October 4, 2023

Genomic Characterization of Locally Recurrent Prostate Cancer after Radiation Therapy. October 4, 2023

Pilot Study of a Novel Ring Gantry-Based PET/CT Linear Accelerator in Patients with Prostate Cancer Receiving [18F]-DCFPyL for PSMA PET Imaging. October 4, 2023

Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. October 4, 2023

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies October 3, 2023

Predicting 18F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical Recurrence. October 3, 2023

Active surveillance should be considered for select men with Grade Group 2 prostate cancer. October 3, 2023

Biopsy and Erectile Functional Outcomes of Partial Prostate Ablation: A Systematic Review and Meta-Analysis of Prospective Studies. October 3, 2023

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer. October 3, 2023

The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial. October 3, 2023

Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. October 3, 2023

Comparative analysis of robot-assisted simple prostatectomy: the HUGO™ RAS system versus the DaVinci® Xi system. October 2, 2023

Oncological and functional results of focal treatment of localized prostate cancer with HIFU. October 2, 2023

Page 104 of 1439